3 Stocks Raising The Health Services Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices traded up today One out of the three major indices traded up today The three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 3.30 points (0.0%) at 17,812 as of Wednesday, Nov. 26, 2014, 3:25 PM ET. The NYSE advances/declines ratio sits at 1,757 issues advancing vs. 1,268 declining with 146 unchanged.

The Health Services industry as a whole closed the day up 0.5% versus the S&P 500, which was up 0.1%. Top gainers within the Health Services industry included USMD Holdings ( USMD), up 3.7%, IMRIS ( IMRS), up 4.1%, Pingtan Marine Enterprise ( PME), up 2.7%, Akers Biosciences ( AKER), up 7.2% and Cesca Therapeutics ( KOOL), up 1.8%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Cesca Therapeutics ( KOOL) is one of the companies that pushed the Health Services industry higher today. Cesca Therapeutics was up $0.02 (1.8%) to $1.11 on light volume. Throughout the day, 35,506 shares of Cesca Therapeutics exchanged hands as compared to its average daily volume of 71,800 shares. The stock ranged in a price between $1.08-$1.13 after having opened the day at $1.08 as compared to the previous trading day's close of $1.09.

Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. Cesca Therapeutics has a market cap of $44.7 million and is part of the health care sector. Shares are up 6.9% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts who rate Cesca Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Cesca Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow.

Highlights from TheStreet Ratings analysis on KOOL go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Health Care Equipment & Supplies industry. The net income has decreased by 19.7% when compared to the same quarter one year ago, dropping from -$2.40 million to -$2.87 million.
  • Net operating cash flow has significantly decreased to -$1.74 million or 197.43% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, CESCA THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • KOOL, with its decline in revenue, underperformed when compared the industry average of 6.9%. Since the same quarter one year prior, revenues slightly dropped by 7.5%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • CESCA THERAPEUTICS INC has improved earnings per share by 42.9% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CESCA THERAPEUTICS INC reported poor results of -$0.39 versus -$0.18 in the prior year. This year, the market expects an improvement in earnings (-$0.33 versus -$0.39).

You can view the full analysis from the report here: Cesca Therapeutics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Akers Biosciences ( AKER) was up $0.20 (7.2%) to $2.99 on light volume. Throughout the day, 12,892 shares of Akers Biosciences exchanged hands as compared to its average daily volume of 25,100 shares. The stock ranged in a price between $2.83-$3.07 after having opened the day at $2.85 as compared to the previous trading day's close of $2.79.

Akers Biosciences has a market cap of $13.0 million and is part of the health care sector. Shares are down 58.9% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

IMRIS ( IMRS) was another company that pushed the Health Services industry higher today. IMRIS was up $0.01 (4.1%) to $0.24 on light volume. Throughout the day, 146,863 shares of IMRIS exchanged hands as compared to its average daily volume of 206,100 shares. The stock ranged in a price between $0.23-$0.25 after having opened the day at $0.23 as compared to the previous trading day's close of $0.23.

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions that enable surgeons to obtain information and make decisions during the course of procedures. IMRIS has a market cap of $13.6 million and is part of the health care sector. Shares are down 83.5% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates IMRIS a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates IMRIS as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, generally high debt management risk, disappointing return on equity and poor profit margins.

Highlights from TheStreet Ratings analysis on IMRS go as follows:

  • Currently the debt-to-equity ratio of 1.58 is quite high overall and when compared to the industry average, suggesting that the current management of debt levels should be re-evaluated. To add to this, IMRS has a quick ratio of 0.66, this demonstrates the lack of ability of the company to cover short-term liquidity needs.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, IMRIS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for IMRIS INC is currently lower than what is desirable, coming in at 34.47%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -121.20% is significantly below that of the industry average.
  • IMRIS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has suffered a declining pattern earnings per share over the past two years. During the past fiscal year, IMRIS INC reported poor results of -$0.83 versus -$0.60 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 120.6% when compared to the same quarter one year ago, falling from -$3.80 million to -$8.39 million.

You can view the full analysis from the report here: IMRIS Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Stocks Waver Amid a Rise in Bond Yields, Strong Earnings

Stocks Waver Amid a Rise in Bond Yields, Strong Earnings

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Video: Jim Cramer Reveals Why He's Cautious on Stocks